ADVERTISEMENT

Departments

Gynecologic Oncology
HPV DNA Co-Testing Adoption and Its Effect on Patient Annual Visits
Garfield S, Gavaghan M, Poret A, Ilika K Susan Garfield, MSc, SM; Meghan Gavaghan, MPH; Amy Poret, SM; Karen Ilika, MD Susan Garfield, MSc, SM; Meghan Gavaghan, MPH; Amy Poret, SM; Karen Ilika, MD Susan Garfield, MSc, SM; Meghan Gavaghan, MPH; Amy Poret, SM; Karen Ilika, MD
The Female Patient. 2010;35(4):53-56

Cervical cancer screening using both an FDA-approved HPV DNA test plus a Pap test (co-testing) is supported by major clinical practice guidelines, but some clinicians may have concerns about implementing this process in their practices. Will patients still come back for their annual examination if they don’t need to be tested yearly? Will reimbursement be a problem? This paper describes a survey of clinicians, with results that may help allay these and other concerns.


ADVERTISEMENT
ADVERTISEMENT

Breaking News

More Headlines